Patent Assignment
Reel/Frame 051780/0821
Assignment of Assignor's Interest
Recorded: 2020-02-11
Pages: 3
Assignor
DURING, MATTHEW
Executed: 2019-03-12
Assignee
OVID THERAPEUTICS INC.
1460 BROADWAY, NEW YORK, NEW YORK, 10036
Covered Properties
(3)
Use of (1S,3S)-3-Amino-4-(Difluoromethylidene) Cyclopentane-1-Carboxylic Acid and (S)-3-Amino-4-(Difluoromethylenyl)Cyclopent-1-Ene-1-Carboxylic Acid in the Treatment of Tinnitus, Acute Sensorineural Hearing Loss, Meniere's Disease, Tourette's Syndrome, Attention Deficit Hyperactivity Disorder and Addiction
Patent:
10,653,652 →
Application:
16/270,856 →
Publication:
US 2019/0240174
PCT:
PCT/US2019/017201 ↗
Use of Gamma-Amino Butyric Acid Aminotransferase Inhibitors in the Treatment of Tinnitus, Acute Sensorineural, Hearling Loss and Meniere's Disease
Application:
62/628,020 →
Use of (1S,3S)-3-Amino-4-(Difluoromethylidene) Cyclopentane-1-Carboxylic Acid and (S)-3-Amino-4-(Difluoromehylenyl)Cyclopent-1-Ene-1-Carboxylic Acid in the Treatment of Tinitus, Acute Sensorineural Hearing Loss, Meniere's Disease, Tourette's Syndrome, Attention Deficit Hyperactivity Disorder and Addiction
Application:
62/628,541 →